Mecamylamine for Autonomic Dysreflexia Prophylaxis
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a preliminary study of the antihypertensive drug mecamylamine, used in the specific
circumstance of hypertension caused by autonomic dysreflexia (AD), a condition that affects
people with spinal cord injury (SCI). Initially, mild sensory stimulation of subjects' legs
is used to intentionally provoke AD, as reflected by blood pressure elevation during such
stimulation. In subsequent testing sessions, mecamylamine is given prior to sensory
stimulation, to show the effect of the drug on preventing these AD-related blood pressure
elevations.